Security National Trust Co. boosted its holdings in Bristol-Myers Squibb Co (NYSE:BMY) by 5.4% during the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 63,253 shares of the biopharmaceutical company’s stock after purchasing an additional 3,247 shares during the period. Security National Trust Co.’s holdings in Bristol-Myers Squibb were worth $3,017,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds and other institutional investors have also modified their holdings of the business. Vanguard Group Inc raised its stake in shares of Bristol-Myers Squibb by 1.0% during the 3rd quarter. Vanguard Group Inc now owns 128,376,159 shares of the biopharmaceutical company’s stock worth $7,969,593,000 after acquiring an additional 1,229,553 shares in the last quarter. First Citizens Bank & Trust Co. raised its stake in shares of Bristol-Myers Squibb by 7.0% during the 4th quarter. First Citizens Bank & Trust Co. now owns 10,732 shares of the biopharmaceutical company’s stock worth $558,000 after acquiring an additional 699 shares in the last quarter. BKD Wealth Advisors LLC raised its stake in shares of Bristol-Myers Squibb by 3.8% during the 4th quarter. BKD Wealth Advisors LLC now owns 22,148 shares of the biopharmaceutical company’s stock worth $1,151,000 after acquiring an additional 815 shares in the last quarter. Personal Capital Advisors Corp raised its stake in shares of Bristol-Myers Squibb by 20.5% during the 4th quarter. Personal Capital Advisors Corp now owns 27,233 shares of the biopharmaceutical company’s stock worth $1,416,000 after acquiring an additional 4,634 shares in the last quarter. Finally, Strategic Wealth Management Group LLC bought a new position in shares of Bristol-Myers Squibb during the 4th quarter worth approximately $212,000. 74.09% of the stock is currently owned by institutional investors.
BMY has been the topic of a number of recent analyst reports. JPMorgan Chase & Co. initiated coverage on shares of Bristol-Myers Squibb in a research note on Friday, May 3rd. They set an “overweight” rating and a $62.00 price target on the stock. BMO Capital Markets restated a “buy” rating and set a $59.00 price target on shares of Bristol-Myers Squibb in a research note on Tuesday, February 19th. Bank of America set a $53.00 price target on shares of Bristol-Myers Squibb and gave the company a “hold” rating in a research note on Friday, January 25th. Barclays upgraded shares of Bristol-Myers Squibb from an “equal weight” rating to an “overweight” rating and upped their price target for the company from $53.00 to $55.00 in a research note on Friday, May 3rd. Finally, Zacks Investment Research upgraded shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $60.00 price target on the stock in a research note on Tuesday, March 5th. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and eight have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $57.64.
Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported $1.10 EPS for the quarter, beating the consensus estimate of $1.09 by $0.01. The business had revenue of $5.92 billion for the quarter, compared to the consensus estimate of $5.72 billion. Bristol-Myers Squibb had a net margin of 22.23% and a return on equity of 48.72%. The business’s revenue for the quarter was up 14.0% on a year-over-year basis. During the same period in the prior year, the firm earned $0.94 EPS. Research analysts forecast that Bristol-Myers Squibb Co will post 4.18 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, May 1st. Stockholders of record on Friday, April 5th were issued a $0.41 dividend. This represents a $1.64 annualized dividend and a dividend yield of 3.50%. The ex-dividend date of this dividend was Thursday, April 4th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is currently 41.21%.
COPYRIGHT VIOLATION WARNING: This story was originally reported by Baseball Daily News and is owned by of Baseball Daily News. If you are viewing this story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this story can be viewed at https://www.baseballdailydigest.com/news/2019/05/18/bristol-myers-squibb-co-bmy-holdings-lifted-by-security-national-trust-co.html.
Bristol-Myers Squibb Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.
Featured Article: What is a short straddle?
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.